Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Occupational and environmental lung diseases, and Wnt/β-catenin signaling in development and cancer.
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
A fibroblast-dependent TGF-β1/sFRP2 noncanonical Wnt signaling axis promotes epithelial metaplasia in idiopathic pulmonary fibrosis
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
SARS-CoV-2 infection of airway organoids reveals conserved use of Tetraspanin-8 by Ancestral, Delta, and Omicron variants
Discovering dominant tumor immune archetypes in a pan-cancer census
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging
Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Expansion of hedgehog disrupts mesenchymal identity and induces emphysema phenotype
Inhibition of yes‐associated protein down‐regulates PD‐L1 (CD274) expression in human malignant pleural mesothelioma
YAP regulates PD-L1 expression in human NSCLC cells
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
Targeting YAP in malignant pleural mesothelioma
Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer
Gli is activated and promotes epithelial-mesenchymal transition in human esophageal adenocarcinoma
Lung Cancer Staging and Prognosis
YAP promotes erlotinib resistance in human non-small cell lung cancer cells
YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells
Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas
NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells
Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas
Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease
Tumor-Infiltrating Regulatory T Cells Inhibit Endogenous Cytotoxic T Cell Responses to Lung Adenocarcinoma
Coumestrol from the national cancer Institute’s natural product library is a novel inhibitor of protein kinase CK2
Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies